

REMARKS

Reconsideration is requested.

Claim 6 has been added and finds support throughout the specification, and claim 1 as originally-filed. No new matter has been added.

The objection to the specification is obviated by the above amendments. The inhibitors of the claims are described in the originally-filed specification. Withdrawal of the objection to the specification is requested.

The Section 112, second paragraph, rejection of claims 1-5 is obviated by the above amendments. Withdrawal of the rejection is requested.

The Section 101 rejection of claims 1 and 2 is obviated by the above amendments.

The Section 102 rejection of claims 1-5 over Krumdieck (U.S. Patent No. 5,650,389) is traversed. Reconsideration and withdrawal of the rejection are requested in view of the following distinguishing comments.

The applicants believe that the cited patent relates to a method for reducing the complement activating potential of an implanted medical device comprising coating the implanted medical device with an effective amount of decorin and that this a technical problem different from the one solved by the present invention which concerns the prevention of intrastent restenose.. The applicants believe that such a problem is not anticipated by the cited patent and that there is therefore no teaching by the cited patent of the an inhibitory effect of extracellular matrix synthesis, migration and inflammation

Withdrawal of the Section 102 rejection is requested.

LAFONT et al.
Appl. No. 10/561,238
Atty. Ref.: 1721-108
Amendment
June 25, 2008

The claims are submitted to be in condition for allowance and a Notice to that effect is requested.

The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100